Gilead Sciences has retired 33.3% of its shares since 2006, from 1,858,655,664 to 1,239,955,155.
At $156.19 a share, a market value of $193.7B. FCF yield 6.7%, P/E n/m, trailing twelve months to June 2026.
| Fiscal year | Date | Shares outstanding | Filing | |
|---|---|---|---|---|
| 1999 | 2000-02-25 | 1,420,442,496 | 10-K405 | cover page |
| 2000 | 2001-02-28 | 1,509,653,024 | 10-K | cover page |
| 2001 | 2002-02-28 | 1,551,993,728 | 10-K | cover page |
| 2002 | 2003-02-28 | 1,588,026,888 | 10-K | cover page |
| 2003 | 2004-02-27 | 1,710,246,296 | 10-K | cover page |
| 2004 | 2005-02-28 | 1,799,527,440 | 10-K | cover page |
| 2005 | 2006-02-28 | 1,849,138,544 | 10-K | cover page |
| 2006 | 2007-02-23 | 1,858,655,664 | 10-K | cover page |
| 2007 | 2008-02-22 | 1,857,740,064 | 10-K | cover page |
| 2008 | 2008-12-31 | 1,819,638,000 | 10-K | |
| 2009 | 2010-02-19 | 1,806,757,972 | 10-K | |
| 2010 | 2011-02-18 | 1,590,529,288 | 10-K | |
| 2011 | 2012-02-10 | 1,514,630,722 | 10-K | |
| 2012 | 2013-02-15 | 1,522,392,518 | 10-K | |
| 2013 | 2014-02-14 | 1,538,252,914 | 10-K | |
| 2014 | 2015-02-13 | 1,489,401,683 | 10-K | |
| 2015 | 2016-02-12 | 1,366,845,691 | 10-K | |
| 2016 | 2017-02-16 | 1,307,066,900 | 10-K | |
| 2017 | 2018-02-15 | 1,309,967,781 | 10-K | |
| 2018 | 2019-02-15 | 1,275,510,558 | 10-K | |
| 2019 | 2020-02-18 | 1,263,636,656 | 10-K | |
| 2020 | 2021-02-18 | 1,256,593,156 | 10-K | |
| 2021 | 2022-02-18 | 1,253,886,724 | 10-K | |
| 2022 | 2023-02-17 | 1,247,105,154 | 10-K | |
| 2023 | 2024-02-16 | 1,245,774,616 | 10-K | |
| 2024 | 2025-02-21 | 1,245,346,062 | 10-K | |
| 2025 | 2026-02-13 | 1,241,420,528 | 10-K |
Source: all 10-K filings of Gilead Sciences on EDGAR. Download this series as CSV. Licence CC BY 4.0, credit Buyback Radar.
The story
Every Monday we write about one of these companies.
Read the full storyCash spent comes from the cash flow statement. Shares outstanding fell by less than the company bought, because part of every buyback only replaces shares handed to employees. Today’s price is $156.19.
Loading the chart from TradingView…
All-time chart by TradingView. Open it on TradingView →
Only enough to stand still. The share count is roughly flat over the last twelve months, at 1,239,955,155 as of July 31, 2026. Over five years the share count is down 1.2%.
Net of every new share it issued, Gilead Sciences has 618.7 million fewer shares than at its 2006 peak. That is 33.3% of the company.
1,239,955,155 shares, as of July 31, 2026, from the cover page of its latest 10-Q. At the 2006 peak it had 1,858,655,664.
Each share is a bigger slice of the company. Someone who held Gilead Sciences stock in 2006 owns 1.5 times as much of the business today without buying another share. Whether that was a good use of cash depends on the price paid.
Gilead Sciences ranks No. 238 of 467 companies on Buyback Radar by share of the company retired since its peak. Close to it on the list: GATX (33.4%), Avery Dennison (33.4%), JPMorgan Chase (33.3%), Trane Technologies (33.2%).
Every answer is computed from Gilead Sciences' own SEC filings and rebuilt every Monday. Latest count: 10-Q on EDGAR.
From the latest 13F filings. All superinvestors.
Free. Your email goes to Substack, which runs the newsletter. Privacy